Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients : A Multicenter International Study
BACKGROUND: The COVID-19 pandemic carries a high burden of morbidity and mortality worldwide. We aimed to identify possible predictors of in-hospital major cardiovascular (CV) events in COVID-19.
METHODS: We retrospectively included patients hospitalized for COVID-19 from 10 centers. Clinical, biochemical, electrocardiographic, and imaging data at admission and medications were collected. Primary endpoint was a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE).
RESULTS: Of the 748 patients included, 141(19%) reached the set endpoint: 49 (7%) CV death, 15 (2%) acute myocarditis, 32 (4%) sustained-supraventricular or ventricular arrhythmias, 14 (2%) cardiocirculatory arrest, 8 (1%) ACS, 41 (5%) AHF, and 39 (5%) PE. Patients with CV events had higher age, body temperature, creatinine, high-sensitivity troponin, white blood cells, and platelet counts at admission and were more likely to have systemic hypertension, renal failure (creatinine ≥ 1.25 mg/dL), chronic obstructive pulmonary disease, atrial fibrillation, and cardiomyopathy. On univariate and multivariate analysis, troponin and renal failure were associated with the composite endpoint. Kaplan-Meier analysis showed a clear divergence of in-hospital composite event-free survival stratified according to median troponin value and the presence of renal failure (Log rank p < 0.001).
CONCLUSIONS: Our findings, derived from a multicenter data collection study, suggest the routine use of biomarkers, such as cardiac troponin and serum creatinine, for in-hospital prediction of CV events in patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 10(2021), 24 vom: 14. Dez. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 28.12.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm10245863 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334810744 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334810744 | ||
| 003 | DE-627 | ||
| 005 | 20231225224511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10245863 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334810744 | ||
| 035 | |a (NLM)34945166 | ||
| 035 | |a (PII)5863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Henein, Michael Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients |b A Multicenter International Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The COVID-19 pandemic carries a high burden of morbidity and mortality worldwide. We aimed to identify possible predictors of in-hospital major cardiovascular (CV) events in COVID-19 | ||
| 520 | |a METHODS: We retrospectively included patients hospitalized for COVID-19 from 10 centers. Clinical, biochemical, electrocardiographic, and imaging data at admission and medications were collected. Primary endpoint was a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE) | ||
| 520 | |a RESULTS: Of the 748 patients included, 141(19%) reached the set endpoint: 49 (7%) CV death, 15 (2%) acute myocarditis, 32 (4%) sustained-supraventricular or ventricular arrhythmias, 14 (2%) cardiocirculatory arrest, 8 (1%) ACS, 41 (5%) AHF, and 39 (5%) PE. Patients with CV events had higher age, body temperature, creatinine, high-sensitivity troponin, white blood cells, and platelet counts at admission and were more likely to have systemic hypertension, renal failure (creatinine ≥ 1.25 mg/dL), chronic obstructive pulmonary disease, atrial fibrillation, and cardiomyopathy. On univariate and multivariate analysis, troponin and renal failure were associated with the composite endpoint. Kaplan-Meier analysis showed a clear divergence of in-hospital composite event-free survival stratified according to median troponin value and the presence of renal failure (Log rank p < 0.001) | ||
| 520 | |a CONCLUSIONS: Our findings, derived from a multicenter data collection study, suggest the routine use of biomarkers, such as cardiac troponin and serum creatinine, for in-hospital prediction of CV events in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a creatinine | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a troponin | |
| 700 | 1 | |a Mandoli, Giulia Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pastore, Maria Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Ghionzoli, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Hasson, Fouhad |e verfasserin |4 aut | |
| 700 | 1 | |a Nisar, Muhammad K |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Bandera, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Marrocco-Trischitta, Massimiliano M |e verfasserin |4 aut | |
| 700 | 1 | |a Baroni, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Malagoli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Biagi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Citro, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarelli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Silverio, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Biagioni, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Moutiris, Joseph A |e verfasserin |4 aut | |
| 700 | 1 | |a Vancheri, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzola, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Geraci, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Liza |e verfasserin |4 aut | |
| 700 | 1 | |a Altman, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Pernow, John |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Ciro |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Casas, Guillem |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Galera, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Maribel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez Palomares, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Bytyçi, Ibadete |e verfasserin |4 aut | |
| 700 | 1 | |a Dini, Frank Lloyd |e verfasserin |4 aut | |
| 700 | 1 | |a Cameli, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Franchi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Bajraktari, Gani |e verfasserin |4 aut | |
| 700 | 1 | |a Badano, Luigi Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Cameli, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 24 vom: 14. Dez. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:24 |g day:14 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10245863 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 24 |b 14 |c 12 | ||